文献速递血脂与心血管预防瓣膜病与结构性心脏病

新冠疫苗接种对英格兰先天性心脏病患者的影响:病例对照研究

The impact of COVID-19 vaccination on patients with congenital heart disease in England: a case-control study.
PubMed 文献 · Heart · 2024-11-19

接种后CHD患者住院率(0.5% vs 15.8%)和死亡率(0.5% vs 4.6%)较接种前大幅下降,但接种后CHD患者较接种对照仍有更高的住院(aOR 2.24)和死亡(aOR 1.81)风险。

要点

  • 接种后CHD患者COVID-19住院和死亡绝对风险显著低于接种前。
  • 接种后CHD患者较无CHD接种者住院风险aOR 2.24、死亡风险aOR 1.81。
  • 无证据显示CHD患者疫苗效力下降更快或心肌炎/心包炎/血栓事件增加更多。

核心结论

  • 接种新冠疫苗后CHD患者COVID-19住院和死亡绝对风险降低,但较无CHD接种者仍有较高严重结局风险。

主要发现

  • 与接种前队列相比,接种后CHD患者COVID-19相关住院率0.5% vs 15.8%,死亡率0.5% vs 4.6%。
  • 与接种对照相比,接种CHD患者住院风险0.5% vs 0.2%,调整OR 2.24(1.88-2.65),p<0.001。
  • 与接种对照相比,接种CHD患者死亡风险0.5% vs 0.3%,调整OR 1.81(1.54-2.13),p<0.001。
  • 无证据表明CHD患者疫苗效力下降更快,或心肌炎、心包炎或血栓事件发生率增加更大。

临床怎么用

  • 应重视CHD人群的新冠疫苗接种,以降低住院和死亡绝对风险。
  • 即使CHD患者已完成疫苗接种,诊疗提供者对COVID-19感染仍需保持警惕。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies predating widespread COVID-19 vaccination identified patients with congenital heart disease (CHD) as a group at increased risk of severe outcomes from COVID-19. Here we evaluate the impact of vaccination on COVID-19 outcomes among patients with CHD. METHODS: We conducted a case-control study using linked English electronic health records (n=3 18 135). Patients with CHD were matched with controls by age, sex, ethnicity and GP practice. The 'prevaccination' cohort comprised unvaccinated patients with CHD and matched controls with first-recorded SARS-CoV-2 infection between 1 March and 8 December 2020 (7805 cases, 27 620 controls). The 'post-vaccination' cohort comprised vaccinated patients with CHD and matched controls with first-recorded SARS-CoV-2 infection between 1 March 2021 and 1 April 2022, at least 14 days after vaccination (57 550 cases, 225 160 controls). Odds of severe COVID-19 outcomes were compared using conditional logistic regression. We also compared the rate at which vaccine efficacy diminished, and the incidence of vaccine-associated complications. RESULTS: Compared with the prevaccination cohort, postvaccination patients with CHD exhibited markedly reduced rates of COVID-19-related hospitalisation (0.5% vs 15.8%) and mortality rates (0.5% vs 4.6%). Compared with vaccinated controls, vaccinated patients with CHD remained at increased risk of hospitalisation (0.5% vs 0.2%, adjusted OR 2.24 (1.88-2.65); p<0.001) and death (0.5% vs 0.3%, adjusted OR 1.81 (1.54-2.13); p<0.001). There was no evidence that vaccine efficacy declined faster in patients with CHD, or that patients with CHD experienced a larger increase in incidence of myocarditis, pericarditis or thrombotic events. CONCLUSION: We observed a lower absolute risk of hospitalisation and death from COVID-19 in CHD patients after vaccination. However, in vaccinated CHD patients, an elevated risk of severe outcomes persists compared with vaccinated people without CHD. These results emphasise the importance of vaccination in the CHD population, and of vigilance among care providers dealing with COVID-19 infection in CHD patients, even if fully vaccinated.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Harrison C, Frain S, Jalalinajafabadi F, et al. The impact of COVID-19 vaccination on patients with congenital heart disease in England: a case-control study. Heart. 2024. PMID: 39393905. doi:10.1136/heartjnl-2024-324470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。